DS5 (Dermaseptin S5)

What is DS5 (Dermaseptin S5)?

DS5, more precisely dermaseptin S5 (DRS-S5), is a cationic, amphipathic, alpha-helical antimicrobial peptide isolated from the skin secretions of the South American sauvage's leaf frog (Phyllomedusa sauvagii). It belongs to the dermaseptin superfamily — a large group of lysine-rich, 27–34 residue peptides first described in the early 1990s by the groups of Amram Mor, Pierre Nicolas, and colleagues. Like the other S-series dermaseptins (S1–S4), DS5 kills microbes by direct membrane disruption: the peptide adopts an amphipathic helix on contact with lipid bilayers, inserts into the membrane, and permeabilises it via a carpet-like or toroidal-pore mechanism. DS5 is important to flag carefully because the identifier "DS5" is used in several unrelated contexts in the peptide and research-chemical literature; this entry covers the dermaseptin interpretation, which is the one with a real PubMed-indexed evidence base. DS5 is a preclinical research peptide. It is not an approved drug, it is not a clinically validated therapy, and it is not a wellness or longevity peptide despite its antimicrobial profile.

What DS5 (Dermaseptin S5) Is Investigated For

Dermaseptin S5 sits in the broader dermaseptin research program — a decades-long academic effort to understand how cationic amphipathic peptides from amphibian skin kill microbes, and whether that biology can be engineered into human-usable anti-infectives. The published work on DS5 is almost entirely in vitro: antimicrobial assays against bacteria, yeasts, filamentous fungi, Leishmania promastigotes, Plasmodium-infected erythrocytes, and enveloped viruses, plus biophysical studies of how DS5 interacts with model lipid bilayers and microbial membranes. The reported therapeutic profile is favourable relative to some of its siblings — DS5 is generally described as having low hemolytic activity against human red blood cells at antimicrobial concentrations, which made it a candidate for chemical optimisation in follow-on work. The honest framing is that DS5 is a research peptide. There are no published human trials, there is no established clinical indication, there are no reliable human pharmacokinetic or safety data, and it is not sold through any regulated therapeutic channel. Anyone searching "DS5 peptide" expecting a BPC-157-style self-administration protocol is looking at the wrong category of molecule — dermaseptins are laboratory tools and drug-development starting points, not consumer peptides.

History & Discovery

Dermaseptins were first described in the early 1990s by Amram Mor, Pierre Nicolas, and colleagues working on the skin secretions of Phyllomedusa tree frogs in collaboration with laboratories in France. The name derives from the animal source (derm-, skin) and the membrane-active family grouping, and the initial papers established the defining structural motif of the group: cationic, lysine-rich, 27–34 residue peptides that adopt an amphipathic alpha-helical conformation on membranes. The S-series (S1 through S5) comes from Phyllomedusa sauvagii and was characterised by that original research lineage; the sibling B-series (dermaseptin b and variants) comes from Phyllomedusa bicolor. The 1994 paper by Mor, Hani, and Nicolas in the Journal of Biological Chemistry — "The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms" — is the canonical reference for how the S-series members, including DS5, differ in target specificity despite sharing a scaffold. The research program that followed went in several directions. One thread focused on mechanism: biophysical work with model lipid bilayers and with live bacteria established the membrane-disruption model now broadly associated with cationic amphipathic antimicrobial peptides. A second thread focused on antiparasitic applications, particularly against Leishmania and Plasmodium, with the J. Rivas and related groups contributing substantial work on dermaseptin membrane interaction with parasite-infected cells. A third thread — the most active in medicinal chemistry — focused on engineering shortened, stabilised, or derivatised analogs with improved selectivity and drug-likeness, with most of that optimisation effort going to dermaseptin S4 rather than S5. DS5 itself has remained largely a reference compound within that family: a useful research tool, a data point in structure-activity relationship work, and a member of the synergistic dermaseptin cocktail in vitro, but not an independent drug-development program in its own right. Despite the long literature trail and the consistent interest in amphibian antimicrobial peptides as a response to antibiotic resistance, no dermaseptin — including DS5 — has reached clinical approval.

How It Works

Dermaseptin S5 is a small peptide from frog skin that kills microbes by punching holes in their cell membranes. Bacterial, fungal, and parasite membranes carry more negative charge than human cell membranes, so the positively charged peptide sticks to them preferentially, folds into a helix on contact, and disrupts the membrane. This broad membrane-based mechanism is why a single peptide can act on bacteria, yeast, parasites, and some viruses at once.

Dermaseptin S5 is a cationic, lysine-rich peptide of approximately 28 residues that adopts an amphipathic alpha-helical conformation upon contact with lipid bilayers. In aqueous solution it is largely disordered; in the presence of a microbial membrane, electrostatic attraction to anionic phospholipid headgroups (phosphatidylglycerol, cardiolipin) and lipopolysaccharide recruits the peptide to the surface, where hydrophobic and hydrophilic faces of the helix align with the membrane. Peptide accumulates on the outer leaflet until a critical local density is reached, at which point it either disorganises the bilayer in a detergent-like "carpet" fashion or organises into transient toroidal pores, in both cases collapsing the membrane electrochemical gradients and permitting leakage of ions and cytoplasmic contents. This mechanism is shared across the dermaseptin superfamily and accounts for the broad spectrum of activity reported for DS5 across gram-positive and gram-negative bacteria, yeasts, filamentous fungi (with the caveat that some literature reports DS5 as less active than its siblings against certain Aspergillus species), Leishmania promastigotes, intraerythrocytic Plasmodium stages, and enveloped viruses. Selectivity for microbial over mammalian membranes derives from the greater negative surface charge of microbial membranes and the absence of membrane cholesterol in bacteria, but selectivity is relative rather than absolute — all membrane-active peptides can be cytotoxic to host cells at high enough concentrations, and the therapeutic window depends on specific sequence features. Dermaseptin family members have also been reported to synergise with each other (in some cases producing a ~100-fold increase in combined activity over individual peptides), suggesting that in the native frog secretion, the dermaseptins act as a cocktail rather than as individual agents.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about DS5 (Dermaseptin S5):

• 01Human clinical trials — no published Phase I, II, or III human trials of dermaseptin S5 exist for any indication; the entire human pharmacology of the molecule is unknown.
• 02In vivo animal infection models for DS5 specifically — the family's preclinical attention has mostly gone to dermaseptin S4 and its engineered derivatives, leaving DS5 itself with a thinner in vivo dataset.
• 03Therapeutic window quantification — the relative selectivity for microbial over mammalian membranes is documented at moderate-resolution in cell culture but has not been quantified across realistic infection models with simultaneous host-toxicity readouts.
• 04Optimal delivery route — antimicrobial peptides face substantial proteolytic degradation, immunogenicity, and pharmacokinetic challenges; the most viable route (topical, local instillation, lipid-vehicle inhalation) for DS5 has not been defined.
• 05Antimicrobial resistance evolution — the membrane-based mechanism is widely claimed to slow resistance, but long-term resistance studies for DS5 specifically (selecting bacteria under sub-MIC pressure for many generations) have not been published.
• 06Translation to engineered derivatives — most medicinal-chemistry effort in the dermaseptin family has targeted S4 rather than S5, so the structure-activity-relationship landscape around DS5 specifically is underexplored.
• 07Comparison with newer engineered antimicrobial peptide classes (e.g., AI-designed AMPs) — generative-model approaches reported in 2026 produce dermaseptin-family-like sequences with activity against gram-negative pathogens, but head-to-head comparison data versus native DS5 has not been published.

Forms & Administration

Dermaseptin S5 exists primarily as a synthetic research peptide used for in vitro assays and biophysical studies. There is no established clinical route of administration, no validated formulation for human use, and no approved dosing regimen. Any use outside of a research setting is not supported by the published evidence.

Common Questions

Who DS5 (Dermaseptin S5) Is NOT For

Drug & Supplement Interactions

No documented or formally characterized drug interactions exist for dermaseptin S5 in humans because no human administration data exists. Theoretical considerations are limited to mechanism-derived speculation. Membrane-active peptides interact with cellular membranes broadly; co-administration with other membrane-perturbing agents (polymyxins, amphotericin B, certain detergent-like compounds, some cationic disinfectants) could in principle produce additive cytotoxicity, though this has not been studied for DS5 specifically. Combinatorial synergy with other dermaseptin family members in vitro is documented as a property of the natural frog secretion cocktail, but no in vivo or clinical synergy data exists. Beyond these speculative considerations, the absence of any human pharmacology dataset means standard drug-interaction discussion does not apply.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions